Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

SALES: The group's first-quarter sales should come at $13.00 billion, according to a consensus of analysts' estimates compiled by Visible Alpha. This compares with $11.83 billion the year before. In ...

The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

The move will also create 12,000 new jobs across the United States, with 6,500 in construction and 1,000 at “new and expanded ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

The so-called 'Most Favored Nations' rule would set drug pricing for Medicare in line with the prices paid by other nations, ...